For research use only. Not for therapeutic Use.
Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE) is an ADC targeting GPC3 (glypican-3). It induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth and can be used in the research of hepatocellular carcinoma (HCC). MW :145.58 KD.
| Catalog Number | I047060 |
| Purity | ≥95% |
| Reference | [1] Endo M, et al. Cancer Res (2018) 78 (13_Supplement): 2747. |
